Effects of Incretin-based Therapies on Kidney Outcomes in Obese Patients without Diabetes

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/0fda342bb99410665464299b28011fe5.pdf
Effects of Incretin-based Therapies on Kidney Outcomes in Obese Patients without Diabetes

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Kazuki
Nakayama
Takayuki Yamada taka.yamada0125@gmail.com Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan *
Shota Obata shotaggg622@gmail.com Stanford University School of Medicine Department of Medicine, Division of Nephrology Stanford, CA United States -
Shunichiro Tsukamoto t206044g@yokohama-cu.ac.jp Yokohama City University Department of Medical Science and Cardiorenal Medicine Yokohama Japan -
Yuki Kawai snow.ebi@gmail.com Saiseikai Yokohamashi Nanbu Hospital Department of Nephrology and Hypertension Yokohama Japan -
Kazushi Uneda uneda@fmu.ac.jp Aizu Medical Center, Fukushima Medical University Department of Kampo Medicine Aizuwakamatsu Japan -
Tetsuro Aoi tetsuro.aoi11@gmail.com Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan -
Kenta Okada cherry@koto.kpu-m.ac.jp Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan -
Kazuki Nakayama kazuki.n.kyoto@gmail.com Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan *
Yuki Obayashi ooba@koto.kpu-m.ac.jp Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan -
Yasuto Sunahara yasuto@koto.kpu-m.ac.jp Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan -
Tomoharu Ida t-ida@koto.kpu-m.ac.jp Omihachiman Community Medical Center Department of Medicine, Division of Nephrology Omihachiman Japan -
-
-
-
-